Floatz logo

Sigvotatug Vedotin

Carcinoma, Non-Small Cell Lung

Pfizerantibody_drug_conjugatePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

1205 Active assets in the Carcinoma, Non-Small Cell Lung cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Sigvotatug Vedotin is also rated in:

head and neck squamous cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
skin squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Her2-receptor negative breast cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →